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One of the main mechanisms by which total body irradiation (TBI) enhances adoptive cell 
transfer (ACT) immunotherapy is by inducing systemic innate immune activation, 
triggered by microbial LPS released from the radiation-injured gut. Although microbial 
LPS is a critical mediator of TBI enhancement, it is unknown whether exogenous 
administration of LPS can augment therapeutic outcome. We report here that 
administration of LPS to non-irradiated animals did not replicate the ACT effectiveness 
seen in irradiated animals. In contrast, however, we found that LPS dramatically 
augmented ACT treatment in irradiated mice. Moreover, bacterial derived TLR agonists 
other than LPS (such as CpG ODN and Monophospholipid A) but not fungi- or virus-
derived signals (such as PolyI:C, Zymosan, Loxoribine, and Imiquimod) improved 
antitumor immune responses in irradiated animals.  Of clinical importance, we found that 
in vitro priming with LPS, CpG or MPL enhanced the anti-tumor activity of transferred 
CD8+ T cells.   While it would be ideal to simply add TLR agonists to APCs to enhance 
their immunogenicity and in turn increase CD8+ T cell function, we must consider the 
potential negative feedback immune-regulatory mechanisms that result from TLR agonist 
priming, such as elevated IL-10 production. We found that transiently neutralizing IL-10 
enhanced anti-tumor activity of CD8+ T-cells. However, priming CD8+ T cells with CpG 
ODN while neutralizing IL-10 did not augment the anti-tumor response in mice. 
Furthermore, we found that IL-10 was necessary to maintain IL-17 production and illicit a 




Chapter 1: Introduction 
 For a variety of reasons, it is not surprising that the skin accounts for more cases of 
cancer than any other organ of the body. It is the largest organ and plays a pivotal role in 
many homeostatic mechanisms. It is divided into 3 layers, the epidermis, dermis and 
hypodermis.1 These layers are comprised of specific cell types that aid in the various 
functions that are critical for host immune-health. Of interest to my thesis, are the 
melanocytes that are found in the epidermis. Melanocytes are responsible for protecting 
the deeper layers of skin from harmful ultra violet radiation by secreting the protective 
pigment melanin.1 
While cancers that arise from melanocytes, or melanomas, account for less than 2% 
of skin cancer, they cause the majority of skin cancer related deaths. The American Cancer 
Society estimates that in 2014, 76,100 new melanomas will be diagnosed and roughly 
9,710 people will die of the disease in the US alone.2 If the disease is diagnosed and treated 
in stage 1b or sooner, the five and ten year survival rates exceed 90% and 85%, 
respectively. However, once the melanoma meets stage II criteria, the five and ten year 
survival rates drop to 81% and 67%, respectively. Unfortunately, patients diagnosed with 
stage IV melanoma face a poorer prognosis with approximately 20% of patients living 
longer than five years.3   
Current treatments vary according to the stage at which the melanoma is diagnosed. 
Typically, melanoma treatment utilizes one or a combination of surgery, immunotherapy, 
targeted therapy, chemotherapy and radiation therapy in an adjuvant, neoadjuvant or 
concomitant fashion. While surgery often provides effective treatment for early-stage 
melanomas, later stage disease often require a more sophisticated and combinatorial 
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treatment approach. A relatively new and burgeoning field for cancer treatment, including 
melanoma, is immunotherapy and adoptive immunotherapy.4 
Immunotherapy, or the use of treatments that bolster and stimulate a patient’s own 
immune system, aids the host’s ability to distinguish cancer cells and ward them off.  This 
approach provides an exciting and hopeful avenue for the future of melanoma treatment. 
Within the last decade new and exciting therapies targeting various aspects of the immune 
system have been developed and applied to the treatment of melanoma. Ipilimumab, 
approved by the FDA in 2011, is a monoclonal antibody that blocks CTLA-4, an inhibitory 
T cell receptor, engagement by CD80 (B7-1) and CD86(B7-2) expressed on tumors and 
host antigen presenting cells.5 In a recent clinical trial, this therapy has mediated a 7% 
objective response rate in patients with advanced melanoma.6   
A similar and more recently developed strategic immunotherapy that is showing 
success in clinical trials are PD1 and PD-L1 blocking antibodies. These monoclonal 
antibody therapeutics prevent the engagement of PD1, an inhibitory receptor expressed by 
activated T cells, by PDL-1 that is expressed by either host antigen presenting cells (APCs) 
or various types of tumors. In recent clinical trials Nivolumab, a monoclonal antibody 
against PD1, has achieved objective tumor regressions in 31% of patients with advanced 
melanoma.5 A deeper understanding of the complexity of melanoma and host immune cell 
interactions will provide a multitude of avenues for developing therapeutic interventions. 
Another therapeutically effective treatment for patients with advanced metastatic 
melanoma is adoptive T cell therapy (ACT). While there are many variations and 
competing paradigms related to the best possible approach, the therapy typically involves 
isolating host-tumor infiltrating lymphocytes (TILs), culturing them to large numbers ex 
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vivo and then re-infusing these autologous cells back into the patient. Early clinical trials 
utilizing TILs in addition to IL-2 with cyclophosphamide for the treatment of patients with 
metastatic melanoma resulted in an overall objective response rate of 52%.8    
More recently, clinical trials using non-myeloablative chemotherapy pretreatment 
(consisting of cyclophosphamide and fludarabine) plus total body irradiation (12 Gy TBI, 
2Gy BID for three days) prior to TIL infusion yielded objective responses up to 72% among 
patients with metastatic melanoma.9,10 Patients receiving this regimen require CD34+ 
hematopoietic stem cells (HSCs) the day following TIL infusion to replenish senescent 
HSCs. Mechanistically, TBI has been shown to enhance the effectiveness of transferred T 
cells via several mechanisms. Published mechanisms include decreasing CD4+CD25+ 
regulatory T cells (T-regs); increasing the availability of homeostatic cytokines by 
removing cytokine “sinks”; activation of APCs via disruption of intestinal homeostasis; 
and stimulation of lymphocytes with HSCs.11-14 Of particular interest are the ways in which 
Toll Like Receptor agonists, a byproduct of intestinal disruptions from TBI, impact tumor 




Indigenous gut microbes play a crucial role in health, ranging from nutrient 
absorption, maintenance of mucosal integrity to the regulation of intestinal immune 
homeostasis.15-17 Many chemotherapeutic regimens compromise intestinal immune 
homeostasis and can induce microbial translocation. This microbial translocation can 
initiate a switch in the host-microbe relationship from mutualistic to pathogenic.18-19 This 
phenomenon is implicated in the exacerbation of the pathogenesis of graft versus host 
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disease (GVHD), inflammatory bowel disease, as well as HIV/AIDS.20-22  However, this 
seemingly deleterious effect has recently been found to be beneficial for cell-based cancer 
therapies.14,23 
 Lymphodepletion with a myeloablative chemo-radiotherapy preparative regimen 
administered prior to adoptive immunotherapy mediates objective immune responses in 
>70% of patients with metastatic melanoma.24 In addition to removal of inhibitory cells, 
our lab reported that innate immune activation via TLR4 signaling was a critical 
mechanism underlying the enhanced effectiveness of TBI in mice.25,18,26,14 The purpose of 
this study is to explore the potential for utilizing LPS and other TLR agonists to enhance 
the effectiveness of transferred tumor-specific CD8+ T cells or Th17 cells at eradicating 
established B16 F10 melanoma.  In addition to TLR agonist priming of CD8+ T cells, we 
investigate how IL-10, produced in response to microbial challenge, affects these TLR-




Chapter 2- Review of Literature 
 
Toll Like Receptor (TLR) agonists 
 One mechanism by which the host innate immune system recognizes pathogen 
invasion is via detection of pathogen associated molecular patterns (PAMPS) by pathogen 
recognition receptors (PRRs). TLRs, a type of PRR, are highly expressed on myeloid 
derived cells of the innate immune system. However, research has also indicated variable 
TLR expression on numerous T cell subsets.27 APC engagement by TLR agonists has been 
reported to enhance antigen presentation and bolster the production of inflammatory 
cytokines through up-regulation of co-stimulatory molecules.28 Thus in an indirect fashion, 
TLR induced maturation and stimulation of dendritic cells has important implications for 
the adaptive immune response.29   
Of the 11 known family members, TLRs 3, 4 and 9 will be the focus of this study.  
The rationale for choosing these TLR agonists is because PolyI:C (TLR3) and CpG (TLR9) 
have been or are currently in clinical trials.30-32 We are using LPS/MPL (TLR4) as a control 
as it builds on the foundation of our finding that TBI augments adoptively transferred CD8+ 
T cells via inducing microbial LPS from the injured bowel; which is in our previous 
manuscript published in the Journal of Clinical investigation.14  
TLRs 3, 4 and 9 
 TLR3 recognizes polyinosinic:polycytidylic acid (poly I:C), a synthetic double 
stranded RNA molecule that mimics viral infection.33  Similarly, TLR9 recognizes 
unmethylated cytosine-phosphate-guanine (CpG) motifs of DNA which are common to 
bacterial genomes and viral DNA. TLR4 recognizes the gram negative endotoxin 
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lipopolysaccharide (LPS). Furthermore, while TLR4 is expressed on the extracellular 
membrane, TLR3 and TLR9 are located within the endosomal compartment of most 
professional APCs.34 Because TLR3 and TLR9 are located in the endosomal compartment, 
they are mainly activated by endogenous viral nucleic acids. However, studies have shown 
TLR3 and TLR9 can induce CD8 T cell responses via enhancing APC cross presentation.35-
39 Conversely, TLR4 signaling does not require phagocytosis of pathogens by APCs and 
its activation via LPS binding can be initiated extracellularly without the need for cross 
presentation. 
TLR signaling 
 In general, TLR signaling involves ligand binding to a leucine-rich repeat motif 
with signal transduction initiated through a cytoplasmic Toll/interleukin receptor (TIR) 
domain.40 These receptors recruit and homodimerize with TIR domain-containing adaptor 
proteins. With the exception of TLR3 and TLR4, myeloid differentiation protein 88 
(MyD88) is the adaptor protein that is required to link the TLR receptors to down-stream 
signaling molecules. TLR3 signals through the adaptor molecule Toll/IL-1R domain-
containing adaptor-inducing IFN-β (TRIF). TLR4 can signal through either MyD88 or a 
TRIF dependent fashion. After MyD88 is recruited, it activates IL-1 receptor-associated 
kinases (IRAKs) and TNF receptor associated factor 6 (TRAF6). Then, this series of 
signaling events activates multiple transcription factors including NFkB. Furthermore, 
TLR signaling through MyD88 can activate the PI-3 kinase pathway, induce IFN 






TLR agonists in cancer immunotherapy 
Conceptually, employing bacteria to mediate cancer progression dates back to the 
late nineteenth century when William B. Coley observed spontaneous tumor regression in 
patients with erysipelas.47 In the late twentieth century, the molecular basis behind the 
effects of bacterial bi-products on the mammalian immune system were uncovered by 
Charles Janeway and his colleagues.48 Their discovery of the direct connection between 
TLR signaling and activation of the innate immune system gave heightened insight into 
that of William Coley’s famous toxin over a century prior. Currently, research with TLR 
agonists and their derivatives for cancer treatment is extensive with many ongoing and 
newly launched clinical trials.32 In this section, I will briefly discuss current FDA approved 
TLR agonists for cancer treatment. I will also highlight previous attempts and potential 
new strategies regarding the utilization of various TLR agonists as anti-oncogenic agents 
against melanoma.   
Currently, only three TLR agonists are licensed by the FDA for use in cancer 
patients.  These include bacillus Calmette Guérin (BCG), an attenuated non-virulent 
Mycobacterium bovis used for the treatment of patients with non-invasive transitional cell 
carcinoma of the bladder, monophosphoryl lipid A (MPL), an LPS derivative used as an 
adjuvant in the HPV-16 and -18 vaccine Ceravix®, and Imiquimod, a guanosine analog 
and imidazoquinoline derivative used as a topical therapy for actinic keratosis, superficial 
basal cell carcinoma and external genitoperitoneal warts.49-51 BCG has been shown to work 
as a heterogeneous TLR2/TLR 4 agonist which is similar to MPL as it also triggers TLR2 
and TLR4.52,53 The topical imiquimod cream, Aldara®, elicits its immunostimulatory 
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effects via TLR7 signaling.54 Although, these are the only three TLR agonists currently 
approved for cancer treatment, many other TLR agonists have been used in clinical trials 
and are currently underway for expanding this anti-oncogenic arsenal. 
Previous attempts by Speiser and colleagues were pursued for treating metastatic 
melanoma in patients by administration of low dose CpG ODN 7909 plus a melanoma 
antigen A (Melan-A) analog.55 They were able to achieve strong antigen-specific CD8+ T 
cell responses in these patients. Interestingly, however the therapy could not effectively 
promote tumor regression. The investigators of the study suggested that this crucial 
shortcoming could be attributed to an increase in regulatory CD25+FoxP3+CD4+ T cells 
(i.e. T regs) at the site of the tumor.56 It is also plausible that this vaccination strategy 
generated tumor-specific T cells that were short lived and overall ineffective. Similarly, a 
clinical trial for treatment of melanoma with Hiltonol™, PolyI:CLC- TLR3 agonist, began 
in 2013 in combination with a personalized peptide-based vaccine.32 This therapy may 
encounter obstacles that accompany other vaccine based treatments for melanoma; as they 
are effective at activating innate and adaptive immune system but they cannot overcome 
the peripheral tolerance that ultimately abrogates tumor regression. 
 The efficacy and optimization of future immunotherapeutic regimens involving 
TLR agonists relies on our ability to combine their distinct immunomodulatory features 
with current and new treatments.  For instance, it is has been shown that combined TLR 
and CD40 signaling can induce potent CD8+ T cell expansion.57 Furthermore, selective 
combinations of TLR agonists can differentially skew immune responses to favor potent 
Th1 responses.58 With this in mind, the next logical step for using TLR agonists for anti-
oncogenic therapy in the clinic will likely be in conjunction with the encouraging 
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checkpoint blockade therapy.6,7 For instance, by administering TLR agonists to patients, 
we are effectively activating the innate and the adoptive immune system. However the 
inhibitory mechanisms such as Treg induction, CTLA-4 or PD-1 engagement by APCs or 
cancer cells prevent a prolonged anti-tumor response. By inhibiting the activation of the 
immune brakes of CTLA-4, PD-1 or Tregs, we could theoretically enhance treatment 
outcomes using TLR agonist therapy. Accordingly, a recent study demonstrated that 
blocking CTLA-4 or PD-1 while locally stimulating with a TLR9 agonist effectively broke 
immune tolerance and enhanced tumor eradication in a murine bladder cancer model.59 
TLR agonist immunotherapies or use of multiple TLR agonists simultaneously for cancer 
treatment will not be a highly fortuitous therapeutic venture without addressing the possible 
immunosuppressive compensatory mechanisms.  
In this present study we propose that another incompletely elucidated role for TLR 
agonists lies in their ability to enhance adoptive T cell therapy regimens. In previous work 
from our lab, we have reported that TLR4 signaling, induced by microbial translocation, 
can enhance the function of adoptively transferred CD8+ T cells .14 In this study we aim to 
identify other mechanisms by which TLR agonists enhance CD8+ adoptive T cell therapies. 
Furthermore, we seek to suppress the immunomodulatory features induced by TLR 
agonists that may impair the effectiveness of tumor-specific T cells to potentially replace 
the need for myeloablative chemotherapy pre-treatments in melanoma patients. Of 
particular interest to us is to block the immunosuppressive cytokine IL-10, which has been 
reported to suppress T cell mediated immunity.60 
The paradoxical role of Interleukin 10 in immunity 
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 Interleukin-10 (IL-10) is a cytokine that serves an important immunosuppressive 
role in response to pathogens by inhibiting inflammatory cytokine production by APCs.61 
Globally, this cytokine protects the host by preventing persistent inflammatory responses 
which can cause damage to the host.62 This damage is evidenced by data in IL-10 deficient 
mice developing inflammatory bowel disease in response to colonization of certain 
microorganisms.63,64 IL-10 production was first discovered in Th2 cells but has since been 
reported in many other adaptive and innate cell types including Th1, Tregs, Th17, CD8+ T 
cells, B cells, macrophages and dendritic cells.65-68, 62 In this section we review the main 
immune cell types that produce IL-10, some of the immunomodulatory effects of IL-10 
and, briefly, how IL-10 might be used in cancer therapies. 
 Given its role in suppressing immune responses to pathogens, it is no surprise that 
IL-10 is produced by cells of the innate immune system in response to pattern recognition 
receptor (PRR) ligation by pathogen-derived products.61 Of note, TLR2, TLR3, TLR4, and 
TLR 9 agonists can stimulate the production of varying amounts IL-10 by macrophages 
and DCs.69,70 It has been reported that macrophages produce the greatest amount of IL-10 
followed by myeloid DCs and low amounts by plasmacytoid DCs in response to TLR 
signaling.71 The degree of IL-10 induction by these innate cell types have been shown to 
correlate with the degree of ERK activation.72 As mentioned previously, IL-10 production 
has also been reported in cells of the adaptive immune system making it an important 
immunomodulator in diverse inflammatory conditions.  
 The main source of IL-10 production in cells of the adaptive immune system stem 
from CD4+ T cell subsets including Th1, Th2, Th17and Treg cells. Moreover, it has been 
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reported that high TCR signaling along with IL-12 production enhances the differentiation 
of IL-10 producing Th1 cells in a STAT4 and ERK dependent manner.73,74 Briefly, IL-10 
production in Th17 cells has been reported to occur in a STAT3 dependent fashion while 
IL-4, STAT6 and GATA binding protein 3 (GATA3) are important for IL-10 production 
in Th2 cells.75-78 While CD4+ lineages are important IL-10 producing cells, CD8+ T cells 
also produce IL-10 following TCR activation by APCs or CD40L interaction on pDCs.65-
68 
In large part, the role of IL-10 is to suppress the effector adaptive immune responses 
and minimize tissue damage in response to microbial infections.79 IL-10 attains this 
function by down regulating MHC complex antigens, intercellular adhesion molecule-
1(ICAM-1) and costimulatory molecules CD80 and CD86 on APCs.80 The role of IL-10 in 
tumor development and treatment remains incompletely elucidated and often times 
contradictory.81  Studies demonstrate that IL-10 is expressed in a variety of human tumors 
including melanomas.81-83 Furthermore, IL-10 production in some human cancers 
correlates with poor prognosis possibly due to an increased number of tumor infiltrating 
DCs and Treg cells which may suppress CD8+ T cell function.84-87 Thus, neutralizing IL-
10 for oncogenic malignancies is an attractive strategy which has shown success in 
preliminary studies involving DC-based vaccine tumor immunotherapies.81 However, there 
are contradictory studies that suggest high levels of IL-10 administration increase an 
effective tumor response by enhancing proliferation and function of tumor infiltrating 
CD8+ T cells.88-89 Indeed, IL-10 producing CD8+ T cells have potent responses to tumor 
antigen.90 Thus, it will be important to neutralize IL-10 to understand how it shapes 
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immunity to tumors. We will explore if blocking IL-10 is an attractive strategy, which has 





Chapter 3-Preliminary Findings 
 
Increasing levels of TBI correlate with depletion of inhibitory lymphocytes, transient 
activation DC activation, and increased impairment of the gastrointestinal tract. 
 
Because intense lymphodepletion with chemo-radiation further enhances ACT 
treatment in patients, it is important to access how increasing the intensity of irradiation 
impacts the degree of host cell depletion and innate activation. To address this question, 
we evaluated the absolute number of splenic lymphocytes and APCs in non-irradiated mice 
compared with mice given a non-myeloablative regimen (5Gy TBI) or mice given a 
myeloablative regimen (9 Gy TBI plus HSC). As expected, we found that increasing the 
intensity of lymphodepletion from 0 to 9 Gy TBI was associated with a greater reduction 
in the absolute number of splenic CD4 and NK cells (Fig. 1A, D3: 0GyTBI: CD4 and NK 
 
Figure 1: Increasing the intensity of lymphodepletion with TBI correlates with greater depletion of 
inhibitory lymphocytes, transient activation of dendritic cells and increased impairment of the 
gastrointestinal tract. A. TBI depletes endogenousCD4 and NK cells and transiently promotes activation 
of CD11c+ dendritic cells. Splenocytes were isolated from 0, 5 and 9 Gy irradiated mice 2-5 days after 
TBI. Mice irradiated with 9 Gy TBI were given HSC. Absolute numbers of CD4, NK and activated 
CD11c+CD86+ DCs in the spleens of TBI and non-irradiated C57BL/6mice were enumerated. Data 
shown are representative of 2 independent experiments. B-C.  High dose TBI compromises the colon. 
Colon of mice werea analyzed at 3 days post-TBI and scored by a pathologist unaware of the treatment 
groups. Data shown (n = 5 mice per group) are representative of 1independent experiment. D.  High dose 
TBI promotes translocation of gut derived LPS. Serum from non-irradiated and 5 or 9 Gy irradiated mice 
were collected and analyzed for the presence of LPS using a LAL assay 6 days after TBI. Data shown (n 





cells –10.6 and 6.45 x 106 splenocytes, respectively). Consistent with previous work, the 
absolute number of activated DCs transiently increased as the intensity of irradiation was 
increased from 0 to 9 Gy TBI (Fig. 1A, Day 1: 0 Gy TBI: CD11c+CD86high cells: 5e3 
splenocytes; 5 Gy TBI: 135e3; and 9Gy TBI+HSC: 211e3 splenocytes).91,14 Collectively, 
our data revealed that increasing the intensity of TBI correlated with greater depletion of 
endogenous lymphocytes and considerable activation of innate immune system. 
We next sought to determine if heightened innate immune activation was associated 
with greater TBI damage to the GI tract. For this, we measured the colon integrity of non-
irradiated mice and mice irradiated with 5 or 9 Gy TBI. Mice irradiated with 9 Gy TBI 
were given HSC support. We found that both 5 and 9 Gy TBI compromised the 
morphological integrity of the gut by pathological score (Fig. 1B and 1C). When compared 
with 5 Gy TBI, 9 Gy TBI appeared to more severely impair the colon, as visually indicated 
by heightened signs of edema as well as by a considerable reduction in crypts and goblet 
cells. A significant amount of LPS, a key component of gram-negative bacterial cell walls 
often measured to determine the degree of microbial translocation, was detected in the sera 
of irradiated mice (Fig. 1D).20,22,14 As expected, a higher amount of LPS was detected in 
the blood of mice receiving 9 Gy TBI (plus HSC) than mice given no or 5 Gy TBI. In 
addition, marked increases in levels of inflammatory cytokines associated with activation 
of the innate immune system — i.e., IL-1 β, IL-6 and IL-12 — were also detected in the 
sera of irradiated mice compared with non-irradiated mice (not shown). Collectively, these 
data revealed that irradiating mice with 9 Gy TBI (plus HSC) further damaged the GI tract 
than seen in 5 Gy TBI mice. Furthermore, greater impairment of the GI tract resulted in 
greater translocation of gut-derived LPS in mice receiving the highest level of irradiation. 
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Addition of ultrapure LPS could not replace the need for TBI.  
Because microbial LPS was detected in the serum of irradiated animals (Fig. 1D), 
we postulated that administering ultrapure LPS to non-irradiated mice would bypass the 
previous need for TBI. To address this idea, we first determined the highest dose of LPS 
that could be tolerated in non-irradiated mice given an ACT therapy. To this end, increasing 
doses of ultrapure LPS, ranging from 0.1 to 10μgs, were administered to non-irradiated 
animals one day after an ACT therapy and their tolerance to treatment was monitored by 
their overall appearance and survival. The ACT therapy was administered consisted of the 
infusion of 5e5 transgenic CD8+ T cells with a TCR that recognizes the gp100 peptide on 
B16 tumors, vaccination encoding gp100 peptide and IL-2 cytokine. In contrast to our 
hypothesis, we found that even the highest tolerable dose of LPS (5μg/mouse) administered 




Figure 2: Administration of ultra-pure LPS does not enhance anti-tumor immunity in 
nonirradiated mice. Ultra-pure LPS does not augment anti-tumor responses in non-irradiated mice. 
Mice bearing s.c. B16 tumors were established for 10 days. Mice received an ACT treatment comprised 
of the adoptive transfer of 5x105 cultured pmel-1 T cells, rFPhgp100 vaccination and rhIL-2 or were left 
untreated. The next day, mice received ultra-pure LPS ranging from 0.1 to 25 μg/mouse or left untreated. 
Data shown (mean ± SEM of 5-10 mice per group) are representative of 2 independent experiments. 
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Addition of ultrapure LPS enhances ACT in mice given non-myeloablative TBI. 
 
We next sought to determine what dose of LPS might safely and effectively 
enhance ACT treatment in animals given a non-myeloablative 5 Gy TBI. Thus, LPS doses 
ranging from 0.1-50μg were administered to irradiated animals one day after treatment. In 
contrast to our findings in nonirradiated animals, we found that 1μg of LPS could 
significantly potentiate CD8+ T cell mediated tumor eradication in irradiated animals. 
Likewise, doses of LPS exceeding 1μg of LPS improved ACT treatment (Fig. 3). Of note, 
we also found that irradiated mice tolerated higher doses of LPS compared to non-
irradiated mice(not shown).  This is likely because TBI ablates APCs activated by this 
agonist that secrete inflammatory cytokines that compromise survival. 
 
Figure 3: Administration of ultra-pure LPS significantly enhanced anti-tumor immunity in 5 Gy 
TBI mice. Ultra-pure LPS augments anti-tumor responses in irradiated mice. Mice bearing s.c. B16 
tumors established for 10 days received 5 Gy TBI. One day after TBI, mice received an ACT treatment 
comprised of the adoptive transfer of 5x105 cultured pmel-1 T cells, rFPhgp100 vaccination and rhIL-2 
or were left untreated. The next day, mice received ultra-pure LPS ranging from 0.1to 25 μg s or left 




LPS increases proliferative capacity and persistence of infused CD8+ T cells. LPS 
increases CD25 but not CD62L expression on infused CD8+ T cells. 
How LPS impacts on the phenotypic signature and proliferative capacity of infused 
tumor -specific CD8+ T cells in vivo remains incompletely elucidated. Thus, we aimed to 
elucidate how LPS influenced the expression of CD62L, CD44 and CD25 on the 
transferred cells in irradiated mice 5 days post treatment. Interestingly, we found that LPS 
greatly increased the expression of CD25, a receptor for IL-2 cytokine, on the transferred 
cells from irradiated mice (Fig. 4A). These data revealed that CD8+ T cells from irradiated 
mice given LPS might have an advantage in acquiring homeostatic cytokine IL-2. In 
contrast to significant differences in CD25 expression due to LPS, there were no 
differences in the expression of CD62L (Fig. 4A) on the transferred cells, likely due to the 
differentiation of the infused cells to a full effector phenotype post infusion into the 
animals. 
 To investigate how LPS impacts on the in vivo proliferative capacity of the infused 
CD8+ T cells, we labeled the infused cells with BRDU and determined the percent of these 
compounds incorporated on day 3 post-transfer. We found that the transferred cells from 
irradiated mice given LPS incorporated significantly more BRDU than in mice receiving 
TBI alone (Fig. 4B). These BRDU data suggested that removing suppressive lymphocytes 
with TBI while concomitantly heightening innate activation by administering a higher 
concentration LPS to the host, unmasked the proliferative capacity of the transferred cells. 
Accordingly, the absolute number of CD8+ T cells was considerably greater in the spleen 
and blood of irradiated mice receiving LPS compared with the absolute number of 
transferred cells in the spleen and blood of irradiated mice not receiving LPS 30 days after 
18 
 
treatment (Fig. 4C and 4D). Collectively, these data indicated that LPS does not merely 
drive the proliferative capacity of infused CD8+ T cells but also increases their persistence 
in irradiated animals. These data might reveal why treatment and survival is superior in 
irradiated mice given LPS after ACT. 
 
CpG ODN and MPL augment the antitumor activity of infused CD8+ T cells. 
Owing to its inherent toxicity, it is important to find alternate agonist to LPS for 
tumor therapy in the clinic. Moreover, some patients have TLR4 polymorphisms, rendering 
their innate immune system resistant to microbial LPS.92 Thus, we sought to determine 
whether TLR2/TLR4 monophospholipid A (MPL-a detoxified version of LPS) could also 
augment ACT treatment in irradiated hosts. Similar to ultrapure LPS, we found that MPL 
was effective in mediating tumor regression by the transferred cells. Importantly, we also 
found that other bacterial-derived agonist beyond LPS could enhance ACT treatment, such 
as CpG ODN (Fig. 5F). Interestingly, no enhanced tumor response was observed in mice 
treated with zymosan, Poly I:C, flagellin, and imiquimod, at least with the doses used in 
 
Figure 4: LPS enhances CD25 expression of adoptively transferred cells and improves their long-
term persistence in vivo. A. LPS enhances the expression of CD25 expression on adoptively transferred 
cells in irradiated mice B. LPS enhances the initial proliferation of adoptive transferred cells as indicated 
via BRDU incoporation at day 3 post-ACT. C-D. LPS increased the absolute number of transferred pmel-
1 T cells in the spleen and blood of irradiated hosts. Absolute numbers of transferred pmel-1 cells 
(CD8+Thy1.1+) in the spleens and blood were enumerated. Data shown (mean ± SEM of 3-5 mice per 




these experiments (Fig. 5A, 5B, 5D, 5E). Collectively, our data revealed other TLR 
agonists besides LPS that can improve cancer-based cellular therapy, such as clinically 
available CpG-ODN, an agonist previously used for tumor immunotherapy in patients.55,93 
In vitro priming of CD8+ T cells with LPS enhanced treatment outcome in mice. 
 
To further lessen the toxicity of LPS while simultaneously bolstering anti-tumor 
activity of adoptively transferred CD8+ T cells, we hypothesized that ex vivo priming CD8+ 
T cells prior to their infusion would augment their antitumor activity in vivo.  Because we 
wash out LPS from the culture before infusing the cells into mice, we capitalize on the 
therapeutic potential of LPS without its toxic side effects.  To address this idea we added 
 
Figure 5: Bacterial derived TLR agonists enhance ACT tumor treatment in irradiated hosts. 
Detoxified LPS (MPL) and CpG augmented antitumor immunity in irradiated mice. Mice bearing s.c. 
B16 tumors established for 10 days received 5 Gy TBI. One day after TBI, mice received an ACT 
treatment comprised of the adoptive transfer of 106 cultured pmel-1 T cells, rFPhgp100 vaccination and 
rhIL-2 or were left untreated. The next day, mice received either A. zymosan (250μg i.v.), B. PolyI:C 
(50μg i.v.), C. detoxifiend LPS – MPL(5μg i.v.), D. Flagellin (200μg i.v.), E. Immiquimod (5% topical 
cream), F. CpG (10μg i.v.) or were left untreated. Data shown (mean ± SEM of 5-10 mice per group) are 




1μg of ultrapure LPS to pmel-1 splenocytes during their in vitro expansion with hgp10025-
33 peptide.  Adding 1μg/mL of ultrapure LPS at the start of the culture and then washing 
out prior to infusion enhanced their in vivo anti-tumor activity compared to cultures not 
primed with LPS (Fig. 6 A). Similar to what was observed with in vivo LPS addition, 
culturing pmel-1 CD8+ cells in vitro with LPS increased CD25, indicating their enhanced 
ability to competitively uptake IL-2 (Fig. 6B). Furthermore, culturing the CD8+ T cells 
with LPS prior to infusion enhanced their ability to persist, which is similar to the results 
when LPS was administered directly to the mice (Figure 5 C-D). Collectively, these results 
indicate the potential to utilize LPS in a non-toxic way by administering the agonist to the 
media during the rapid expansion phase of host TILs instead of directly to the host.  
 
 
Figure 6: In vitro priming with LPS enhanced in vivo anti-tumor activity of adoptively transferred 
P-mel-1 CD8+ T cells. A.  Mice bearing s.c. B16F10 melanoma established for 11 days received 5 Gy 
TBI 12 hours prior to infusion of 1.56 cultured P-mel-1 T cells. 1ug/mL of ultrapure LPS was added to 
the P-mel-1 culture one time at the start of the cultures.  Cells were washed 3x with PBS to ensure limited 
TLR exposure in vivo.  B. In vitro priming with LPS enhanced CD25 expression of cultured P-mel-1 
VB13+ T cells.  C-D. In vitro priming with LPS increased engraftment and persistence of adoptively 




Chapter 4- Effects of TLR agonists and IL-10 on antitumor T cells: 
 
Rationale:  
Our data indicates the potential use of different TLR agonists, especially LPS, in a 
non-myeloablative regimen to improve the activity of tumor specific CD8+ T cells. The 
aim after acquiring the previous data was to elucidate the issues that prevent the practical 
translation of this work in the clinic. Since LPS is a highly toxic compound, it is necessary 
to establish the potential of utilizing other clinically relevant and less toxic TLR agonists 
such as CpG and polyI:C instead of LPS in ex vivo ACT protocols. Even though the TLR 
agonists are not completely interchangeable at eliciting their immunomodulatory effects, 
we hope to identify safe alternatives that ultimately improve anti-tumor CD8+ T cell 
function. Second, although TLR agonists are capable of potentiating a potent immune 
response, it is often accompanied with an equally strong suppressive response. For 
instance, one of the reasons a high dose of TBI is required prior to adoptive cell therapy is 
to rid the body of the immunosuppressive T-reg cells.12 Thus, while it would be ideal to 
simply add TLR agonists to APCs to enhance their immunogenicity and in turn increase 
CD8+ T cell function, we must consider the potential negative feedback mechanisms that 
result from such priming. 
IL-10, a focal interleukin in this study, is an immunosuppressive cytokine that is 
produced in response to TLR signaling in a variety of immune cells.94  IL-10 production 
was first reported in Th2 cells but has recently been reported in Th1, Tregs, Th17, 
macrophages, DCs and CD8+ T cells following TCR activation or interaction with CD40 
ligand by activated pDCs.65-68  It has recently been shown that DCs deficient of IL-10 were 
capable of activating a stronger anti-tumor Th1 and CTL response compared to wild-type 
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DCs.95 Thus, we posit that neutralizing IL-10 during initial priming will further enhance 
the anti-tumor effectiveness of our TLR agonist primed tumor specific CD8+ T cells.  
Results: 
CpG ODN increases both IFN-γ and IL-10 secretion by pmel-1 CD8+ T cells. 
 
We sought to determine how TLR agonists impact the functional capacity of tumor-
specific CD8+ T cells.  We hypothesized that culturing CD8+ T cells with different TLR 
agonists would differentially regulate their capacity to produce IFN-γ. Due to IL-10’s role 
in limiting inflammation, we suspected that TLR agonists would increase IL-10 production 
by T cells.60 After thorough investigation of previous literature TLR agonists 
concentrations were identified to stimulate pmel-1 CD8+ T cells. We used 1-5μg/mL LPS, 
10μg/mL MPL, 20μg/mL PolyI:C and 0.5-5 μg/mL CpG ODN 1668 (CpG ODN or CpG) 
to prime T cells. Specifically, using these concentrations, we stimulated pmel-1 
splenocytes with gp10025-33 peptide plus each of the TLR agonists and rhIL-2 [100IU/mL] 
for 3d and collected supernatant to analyze IFN-γ and IL-10.  
As shown in Figure 7A, priming pmel-1 splenocytes in the presence of LPS, MPL 
or CpG increased their secretion of IFN-γ compared to pmel-1 CD8+ T cells either given 
no TLR agonists or PolyI:C.  However, IL-10 production was increased only by the 
addition of LPS or CpG (Fig. 7B). While these data reveal that TLR4 and TLR 9 agonists 
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augment CD8+ T cell function, it remains unclear if these agonists augment their function 
directly or indirectly via antigen presenting cells.  
Due to the fact that pmel-1 splenocytes contain a heterogeneous population of 
various immune cells, including innate immune cells, we sought to modify the culture 
technique to address if the TLR agonists were acting through the antigen presenting cells 
(APC) or on the CD8+ T cells directly. Accordingly, C57/BL6 splenocytes were pulsed 
with TLR agonists overnight, washed three times with PBS, exposed to 10Gy irradiation 
and loaded with gp10025-33 peptide. In one experimental arm, pmel-1CD8
+ T cells were 
Figure 7 
 
Pmel-1 CD8+ T cells were combined with the splenocytes at 5:1 (pmel-1:/BL6). Supernatant was 
collected 3 days later and an ELISA was performed.   
 
Figure 7: CpG increases IFN-γ and IL-10 
secretion by CD8+ T cells A. Activation of 
pmel-1 CD8+ T cells with hgp10025-33 [1ug/mL] 
in the presence of LPS [1μg/m/L] , MPL 
[10μg/m/L], PolyI:C [20 μg/m/L] or CpG ODN 
[5 μg/m/L] enhanced IFN-γ production via 
ELISA on d4 post activation. B. Priming pmel-1 
CD8 cells with CpG enhanced their capacity to 
secrete IL-10 compared to LPS. C. LPS and CpG 
augment IFN-g by pmel-1 CD8+ T cells only 
when stimulated in an antigen specific manner 
with hgp10025-33 peptide. As feeder cells, BL6 
splenocytes were irradiated with 10Gy, pulsed or 




purified from bulk splenocytes via a negative CD8+ T cell selection kit and combined with 
the TLR primed, gp10025-33 loaded and irradiated APC-containing C57/BL6 splenocytes. 
To control for the possibility that TLR priming alone caused an increase in IFN-y 
production without activating pmel-1 CD8+ T cells, TLR primed C57/BL6 splenocytes 
were not loaded with peptide but combined with purified CD8+ pmel-1 T cells. For this 
experiment, LPS and CpG were the only TLR agonists used primarily because they were 
the only two shown to increase both IFN-γ and IL-10 production in culture. As expected, 
pmel-1 cells primed with TLR agonists without activation did not secrete IFN-γ (Fig. 7C). 
However, pulsing C57/BL6 cells with LPS or CpG and gp10025-33 peptide yielded 
significant increases in IFN-γ production. This data suggests that TLR agonists act in an 
indirect fashion through the APC compartment to stimulate the production of IFN-γ by 
tumor-specific CD8+ T cells.  
CpG augments CD25 and ICOS expression on pmel-1 CD8+ T cells. 
Given our finding that TLR4 agonists enhance pmel-1 CD8+ T cells, we next 
determined how TLR agonists impacted their activation status. We hypothesized that TLR 
agonists would increase the activation of pmel-1 CD8+ T cells, which might account for 
their heightened secretion IFN-γ. Thus, we activated pmel-1 CD8+ T cells with gp10025-33 
peptide with or without TLR agonists.  Cells were expanded for 5 days with rhIL-2 
[100I.U./mL] and then stained for various activation markers. Analysis via flow cytometry 
indicated increased MFI of CD25, the alpha chain of IL-2 receptor, for the samples that 
were stimulated in the presence of LPS, MPL, PolyI:C or CpG (Fig. 8A B).  CD25 was 
significantly increased in samples stimulated with LPS or CpG (Fig. 8B). Furthermore, the 
inducible T cell costimulatory (ICOS) was upregulated in cells stimulated with LPS or CpG 
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during activation and expansion with hgp10025-33 as indicated by an increase in MFI (Fig. 
8A and B). These data reveal that TLR4 and TLR9 agonists potentiate the activation status 
of tumor-specific CD8+ T cells. How the immunosuppressive cytokine IL-10, induced by 
these agonists, impacts their activation status remains unknown.  
 
Figure 8: CpG augments the expression of the activation markers CD25 and ICOS on pmel-1 CD8+ 
T cells. A. Representative histograms of flow cytometry samples comparing relative expression of CD25 
and ICOS. TLR agonists LPS, MPL, PolyI:C or CpG increase CD25 expression on pmel-1 CD8+ T cells. 
LPS and CpG but not MPL or PolyI:C enhances ICOS expression on pmel-1 CD8+ T cells. Extracellular 
staining was performed 5-6 days post after initial stimulation. B. Average MFI of CD25 and ICOS of 




Transient IL-10 blockade augments the activation of CpG-primed CD8+ T cells. 
Because CpG induces marked IL-10 secretion by pmel-1 splenocytes in vitro, we explored 
the effects of IL-10 on T cell activation. We used a purified α-mouse CD210R monoclonal 
antibody (1b1.3a) to neutralize IL-10 in the culture. It has previously been reported that 
IL-10 regulates macrophage and DC immunostimulatory responses to CpG.96-97 Blocking 
IL-10 also increases ICOS expression on Th17 cells in a colitis model.98 Thus, we posit 
that neutralizing IL-10 while priming cells with CpG would increase CD25 and ICOS.  We 
found that transiently neutralizing IL-10 alone increased CD25 compared to control and 
the simultaneous addition of CpG further increased CD25 compared to CpG alone (Fig. 9 
A&B).  However, the addition CpG and depletion of IL-10 did not further upregulate CD25 
 
Figure 9: Transient neutralization of IL-10 augments the activation status of CD8+ T cells primed 
with CpG ODN. A. Flow cytometry histogram showing relative expression of CD25 and ICOS for CpG 
ODN stimulated P-mel-1 splenocytes with or without transient neutralization of IL-10. Samples were 
stained for cytokines and fixed six days post initial stimulation. 10μg/mL of the monoclonal IL-
10(1b1.3a) antibody was added to designated samples at the start of the culture B. Bar graph 
demonstrating ICOS and CD25 MFI of the same samples represented in panel A. The CD25 and ICOS 





on pmel-1 T cells. Contrary to our hypothesis, we did not see an increase in ICOS when 
IL-10 was neutralized compared to control T cells. However, when IL-10 is blocked in the 
presence of CpG, ICOS increased on pmel-1 CD8+ T cells (Fig. 9A & B). This data suggest 
that IL-10 regulates ICOS expression via TLR stimulation, however, these data are 
preliminary and thus need to be repeated increase confidence in the results.  
CpG promotes the generation of central memory pmel-1 CD8+ T cells. 
Central memory T cells regress tumor to a greater extent than effector memory T 
cells when infused into mice.99 Thus, we sought to determine how TLR agonists impacted 
the memory profile of pmel-1 CD8+ T cells ex vivo. To do this, CD44 and CD62L 
expression was analyzed via flow cytometry to detect central (CD44+CD62L+)/effector 
(CD44+CD62L-) memory cells on day 5. All agonists increased central memory cells in the 
culture, as shown by flow, pie and bar graphs (Fig.10 A-C). Interestingly, CpG robustly 
promoted the generation of central memory CD8+ T cells compared to other agonists. This 
enhanced CD62L expression is characteristic of a more central memory type T cell as well 
as their capacity to traffic to the lymph node, which has been shown by Klebanoff, 
Gattinoni and colleagues to correlate with cells that potently regress tumors.99 
IL-10 blockade impairs the generation of central memory pmel-1 CD8+ T cells.  
Next, we wanted to determine how neutralizing IL10 impacted the memory 
phenotype of CpG-activated CD8+ T cells, given that CpG induces IL-10 secretion by T 
cells. Interestingly, we found that transient neutralization of IL-10 decreased the proportion 
of central memory cells compared to control pmel-1 CD8+ T cells, as shown by flow, pie 
chart and bar graph form (Fig. 11A-C).  This diminished expression, along with high CD44 
expression indicates an effector CD8+ T cell phenotype.98 Furthermore, when αIL10R was 
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combined with CpG, the pmel-1 CD8+ T cells expressed fewer central memory cells 
compared to those only primed with CpG. This data suggests that CpG stimulation of CD8+ 
T cells increases their central memory phenotype (CD44+CD62L+), perhaps via IL-10. 
TLR agonists differentially regulate the in vitro cytotoxicity of pmel-1 CD8+ T cells. 
Next, we determined how TLR agonists and/or IL-10 neutralization regulated the 
cytotoxic capacity of tumor-specific CD8+ T cells. We hypothesized that TLR agonists 
would augment T cell cytotoxicity via stimulating APCs to express MHC and secrete IL-
12.  As a feedback mechanism, IL-10 is a common cytokine that is released by multiple 
 
Figure 10: CpG promotes the generation of central memory pmel-1 CD8+ T cells. A. Representative 
flow cytometry analysis of CD44 and CD62L expression on TLR primed pmel-1 splenocytes. All samples 
were stained and fixed on day six and gated for CD8+ and Vβ13+ expression. Addition of LPS, MPL, 
PolyI:C and CpG ODN increases the expression of CD62L for CD44 positive tumor-specific T cells 
compared to control. CpG ODN most robustly augments the generation of central memory CD8+ T cells. 
B. Pie chart showing percentages of cells expressing CD44 and/or CD62L on pmel-1 CD8+ T cells post 
priming with TLR agonists. The chart shows the average percentages of the populations obtained from 
four separate experiments. C. Bar graph representation of flow cytometry data for CD44 and CD62L 
expression of TLR agonist stimulated, CD8+ VB13+ P-mel-1 splenocytes. Data obtained from four 




cell types in response to TLR signaling.62,65 Thus by removing the immunosuppressive 
effects of IL-10, we also expected that T cells would be more cytotoxicity upon antigen 
specific re-stimulation. We expected to observe an increase of TNF-α and Granzyme A/B 
production by pmel-1 CD8+ T cells primed under these conditions. To address this 
question, pmel-1 splenocytes were activated with gp10025-33 peptide with or without TLR 
agonist and then expanded with IL-2 for five days. The cells were then re-stimulated with 
C57/BL6 splenocytes loaded with gp100 peptide. Cells were stained for various cytotoxic 
cytokines and then analyzed via flow cytometry. We found that blocking of IL-10 or the 
addition of the TLR agonists LPS or MPL increased the secretion of granzyme A 
 
Figure 11: IL-10 blockade impairs the generation of central memory pmel-1 CD8+ T cells. A. Flow 
cytometry analysis of CD44 and CD62L expression on pmel-1 splenocytes primed with CpG ODN and/or 
transiently neutralized of IL-10. All samples were stained and fixed on day six and gated for CD8+ and 
VB13+ expression. Transiently neutralizing IL-10 alone via IL10 monoclonal antibody decreased the 
expression CD62L on CD44 positive CD8+ T cells. B. Pie chart of flow cytometry data showing 
percentages from the four possible populations of CD44 and CD62L expression of CD8+ VB13+ pmel-1 
splenocytes primed with CpG and or neutralized of IL-10. C. Bar graph representation of flow cytometry 




production by pmel-1 cells (Fig. 12). LPS, MPL, PolyI:C or CpG increased the percentage 
of granzyme B positive CD8+ pmel-1 T cells. TNFα production was increased by the 
addition of MPL or the transient neutralization of IL-10 but decreased by addition of LPS, 
PolyI:C, or CpG. Taken together, these results indicate that priming pmel-1 T cells with 
TLR agonists differentially regulate the in vitro cytotoxic cytokine production of CD8+ 
pmel-1 splenocytes.  Furthermore, transiently neutralizing IL-10 also enhances their 
effector function.  
 
Pmel-1 CD8+ T cells primed with CpG regress melanoma and extend survival in mice: 
After discovering a multitude of seemingly beneficial effects that TLR agonists 
have on pmel-1 CD8+ T cells, we determined that they were useful for stimulating potent 
anti-tumor responses in an in vivo adoptive cell therapy (ACT) model. We postulated that 
 
Figure 12: TLR agonists differentially impact the in vitro cytotoxicity of pmel-1 CD8+ T cells.  Pmel-
1 splenocytes were cultured for 5ds in the presence of LPS, MPL, PolyI:C, CpG ODN or IL10 antibody 
or a combination of CpG ODN and IL10R. The V13+ CD8+ T cells were activated with hgp10025-33 
peptide pulsed irradiated C57/BL6 splenocytes. Extracellular and intracellular staining of granzyme A/B, 
and TNF was performed 6hrs post re-challenge. 
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T cells primed with LPS or CpG would most effectively control tumor growth and prolong 
survival in melanoma bearing mice, given that cells primed with these agonists generated 
highly function central memory T cells.  As represented in Fig. 13A, C57/BL6 mice were 
injected subcutaneously on the abdomen with 3e5 B16F10 cells and allowed to develop 
tumor for 8 days prior to infusion of T cells primed with various TLR agonists. 6 days prior 
to infusion, pmel-1 mice were sacrificed and T cell cultures were started using splenocytes 
gathered from these animals. Pmel-1 T cells were expanded with gp10025-33 peptide 
[1μg/mL], IL-2 [100I.U./mL] and effective doses of the TLR agonists LPS, MPL, PolyI:C 
or CpG. On the day prior to infusion, mice were given 5Gy TBI and pmel-1 T cells were 
re-stimulated with irradiated hgp10025-33 splenocytes.  The following day, cells were 
washed 3X prior to the infusion of 6e5 pmel-1 T cells into tumor-bearing mice. 
Additionally, mice received rhIL-2 complex (1.5ug rhIL-2 + 7.5ug αhIL-2) on the day of 
infusion to aid the expansion of the adoptively transferred T cells. We found that tumors 
grew rapidly in mice treated with only 5Gy TBI and IL-2 complex and met their endpoint 
for tumor size within 21 days post T cell infusion (Fig. 13B-D).  Mice that received pmel-
1 T cells had their tumors grow slightly slower than control and approximately 30% were 
alive 27 days post T cell infusion. The next best treatment group, although not by a large 
margin, was the PolyI:C primed T cells followed by LPS primed and MPL primed T cells 
(Fig. 13B-D). Interestingly, pmel-1 CD8+ T cells primed with CpG were most effective at 
regressing melanoma and extending survival in mice (Fig. 13B-D). In fact, mice that 
received the CpG primed T cells had 100% survival 27 days post infusion compared to 
approximately 30% of the mice that received pmel-1 T cells without the priming. This data 
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closely models the experiments where the TLR agonists were given directly to the mice 
receiving pmel-1 T cells (Fig. 5). However, this method of utilizing TLR agonists ex vivo 
to augment adoptively transferred T cells in vivo is more clinically translatable because the 
TLR agonists are never directly exposed to the patient.  
 
 
pmel-1 CD8+ T cells were re-stimulated with irradiated and hgp10025-33 loaded C57/BL6 splenocytes 
overnight and washed 3X with PBS prior to tail-vein infusion. Mice also received rhIL-2 complex (1.5ug 
Il-2 + 7.5ug ahIL-2) on the day of infusion via IP injection. B. Individual tumor curves of mice bearing 
B16F10 tumors (n=6-10). C. Comparison of average tumor burden of mice receiving 5 GY TBI, and 
pmel-1 T cells or TLR agonist primed pmel-1 T cells (mean ± SEM of 6-10 mice per group). D. Survival 
curve representing the proportion of tumor bearing mice alive following pmel-1 T cell infusion. 
 
Figure 13: Pmel-1 CD8+ T cells primed 
with CpG regress melanoma and extend 
survival in mice. A. B6 mice bearing s.c. 
B16F10 tumors (established for 8 days) 
were preconditioned with 5 Gy TBI. One 
day after TBI, mice were infused with 6e5 
pmel-1 T cells that were cultured with 
different types of TLR agonists, i.e. LPS 
[1μg/mL], MPL [10μg/mL], PolyI:C [20 





IL-10 blockade augments the antitumor activity of CD8+ T cells in mice. 
Next, we determined how neutralizing IL-10 during T cell expansion impacted the 
ability of transferred CD8+ T cells to control tumor growth in vivo. We hypothesized that 
neutralizing immunosuppressive IL-10 during T cell expansion would enhance the in vivo 
anti-tumor response of adoptively transferred T cells.  Furthermore, we suspected that 
neutralizing IL-10 while simultaneously priming cells with CpG would yield the most 
potent anti-tumor response. As represented in Fig. 14A, B6 mice were injected 
subcutaneously on the abdomen with 3e5 B16F10 cells and allowed to develop tumor for 
8 days prior to receiving adoptive cell therapy. 6days prior to infusion, pmel-1 mice were 
sacrificed and T cell cultures were started using splenocytes gathered from these animals. 
Pmel-1 T cells were expanded with gp10025-33 peptide [1μg/mL], IL-2 [100I.U./mL], CpG 
ODN [5μg/mL] and/or αIL-10 monoclonal antibody [10μg/mL]. On the day prior to 
infusion, mice were given 5Gy TBI and pmel-1 T cells were re-stimulated with irradiated 
hgp10025-33 splenocytes.  The following day, cells were washed 3X prior to the infusion of 
6e5 pmel-1 T cells into tumor-bearing mice. Additionally, mice received rhIL-2 complex 
(1.5ug rhIL-2 + 7.5ug αhIL-2) on the day of infusion to aid the expansion of the adoptively 
transferred T cells. We found that transiently neutralizing IL-10 during the expansion of 
tumor-specific CD8+ T cells enhanced their in vivo anti-tumor capacity and prolonged 
survival in B16F10 tumor bearing mice (Fig. 14B-D). Transiently neutralizing IL-10 
during in vitro expansion allowed the T cells to thwart melanoma growth comparable to 
cells primed with CpG alone.  In contrast to our hypothesis, however, the neutralization of 
IL-10 while concomitantly priming pmel-1 T cells with CpG did not generate a synergistic 
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anti-tumor effect. This data might suggest that extracellular IL-10 does not hinder the 






All pmel-1 T cells were re-stimulated with irradiated and hgp10025-33 loaded C57/BL6 splenocytes 
overnight and then washed 3X with PBS prior to tail-vein infusion. Mice also received IL-2 complex on 
the day of infusion via IP injection. B. Average tumor burdens comparing the effects that transiently 
neutralizing IL-10 has on pmel-1 T cells that are primed with CpG or not (mean ± SEM of 6-10 mice per 
group).  C. Individual tumor curves of mice bearing B16F10 tumors and treated with modified P-mel-1 
T cells (n=6-10). D. Mice that received T cells that were expanded in the presence of IL-10 neutralizing 
antibody survived longer compared to those mice that received pmel-1 T cells without further 
modification. Survival curve represents the proportion of tumor bearing mice alive following pmel-1 T 
cell infusion. 
Figure 14: Transiently neutralizing IL-
10 during expansion of tumor-specific 
CD8+ T cells enhanced their in vivo anti-
tumor capacity and prolonged survival 
in B16F10 tumor bearing mice. A. Mice 
bearing s.c. B16F10 tumors established 
for 8 days received 5 Gy TBI. One day 
after TBI, mice received 6e5 pmel-1 T 
cells that were cultured with CpG 
[5μg/mL], aIL10 antibody [10μg/mL] or 




CpG promotes the functional plasticity of TRP-1 Th17 cells ex vivo. 
After discovering the benefits of priming CD8+ T cells with CpG, we wanted to 
uncover the effects that this agonist imparted on IL-17 producing CD4+ T cells, called Th17 
cells. We were particularly interested in Th17 cells because these cells have shown promise 
in various preclinical models of cancer.100 Because CpG ODN causes an increase in IFN-γ 
production by CD8+ T cells in an APC dependent manner (Fig. 7C) we hypothesized that 
CpG ODN would promote the functional plasticity, or the conversion of IL-17 producing 
cells to those that make IFN-γ, of TRP-1 Th17 cells. Also based on experiments outlined 
previously, we hypothesized that simultaneously neutralizing IL-10 would further the 
effects that CpG ODN has on Th17 cell function.  
To address these ideas, we polarized TRP-1 CD4+ T cells towards a Th17 lineage 
(described in materials and methods section) in the presence of CpG and/or αIL-10 
monoclonal antibody. We then allowed the cells to expand for 7 days before stimulating 
with PMA plus Ionomycin and analyzing their ability to secrete IL-17 and IFN-γ via flow 
cytometry. We found that CpG ODN enhanced the functional plasticity of Th17 cells as 
indicated by an increase in the percentage of IFN-γ secreting cells and decrease in IL-17 
producing cells (Fig. 15A&B). Th17 plasticity was further enhanced when IL-10 was 
simultaneously blocked with CpG activation (Fig. 15A&B).   
To determine the cytokine cues that promote Th17 plasticity via TLR activation 
and IL-10 blocking, supernatant was collected four days post Th17 polarization and various 
cytokines were assayed with by multi-analyte analysis. After analyzing the data, several 
cytokines were markedly elevated in samples that received CpG alone or in conjunction 
with αIL10. These include IL-3, IFN-γ, MCP-1, Rantes (CCL5) and GM-CSF (not shown). 
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Furthermore, the IL-12 p40 subunit was markedly elevated in samples that received CpG 
ODN (Fig. 15C). IL-12(p70) was also increased but to a lesser degree than the IL-12 p40 
subunit (not shown).  
Given that CpG induces IL-12, we hypothesized that this cytokine was responsible 
for the enhanced ability of Th17 cells to secrete IFN-γ. To test this idea, we neutralized IL-
12 with a monoclonal antibody against IL-12(p40) [10μg/mL]. We found that neutralizing 
IL-12p40 partially prevented the functional plasticity of Th17 cells as indicated by a 
decrease in the percentage of IFN-γ producing T cells (Fig. 15D vs. 15A). However, IL-17 
was not completely maintained compared to control suggesting that other cytokines 
induced by CpG enhanced the functional plasticity of Th17 cells. 
Simultaneously neutralizing IL-10 while priming Th17 cells with CpG decreases the 
long-term in vivo anti-tumor activity of adoptively transferred Th17 polarized TRP 
cells. 
 
After discovering that the addition of CpG to Th17 polarizing conditions enhanced 
the ex vivo functional plasticity of TRP-1 Th17 cells, we determined how this impacted 
their ability to eradicate melanoma in vivo. Previous research by Muranski and colleagues 
shows that tumor-specific Th17 cells are superior to Th1 cells at eradicating large 
established melanoma in a mouse model.100 Given that CpG caused Th1 polarization in the 
presence of Th17 cytokines, we hypothesized that these CpG primed Th17 cells would 
have diminished capacity to eradicate established melanoma. Thus, we injected C57/BL6 
mice bearing subcutaneous B16F10 tumors established for 15 days with 1.5e6 CD4+ TRP-
1 cells polarized towards a Th17 lineage in the presence of CpG ODN and/or aIL10 
monoclonal antibody (Fig. 16A). As part of the adoptive therapy protocol, all tumor 
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bearing mice received 5Gy TBI 1 day prior to T cell infusion.  Additionally, T cells were 
re-stimulated O/N with TRP peptide-loaded C57/BL6 splenocytes prior to infusion. 
As shown in Fig. 16B&C, all mice in the group that received only 5Gy TBI were 
euthanized due to growth in tumor size within 14 days post infusion. We also found that 
mice treated with Th17 polarized TRP-1 T cells profoundly regressed tumors. Mice 
receiving Th17 cells that were polarized in the presence of CpG or αIL-10 had similar 
effectiveness and prolonged anti-tumor responses compared to mice receiving Th17 
control cells. As predicted, TRP-1 CD4+ T cells polarized in the presence of both CpG and 
αIL-10 were less effective in regressing tumors. These data indicate that IL-10 is an 
 
Figure 15: CpG ODN promotes the functional plasticity of TRP-1 Th17 cells ex vivo. A. TRP-1 CD4+ 
T cells were polarized using cytokines towards a Th17 lineage in the presence of CpG [5μg/mL] and/or 
aIL10 [10μg/mL]. CpG enhances the production of IFN-γ and simultaneously neutralizing IL-10 further 
enhanced the percentage of IFN-γ producing cells in the samples. B. CpG decreases the relative 
expression of IL-17 while increasing the relative expression of IFN-γ. Transiently neutralizing IL-10 
while stimulating cells with CpG markedly enhanced production of IFN-γ. Relative expression was 
achieved from 3 separate experiments using flow cytometry as the assay. The percentage of cells 
producing IL-17 or IFN-γ for the control Th17 sample was used to standardize the relative expression for 
each experiment. The relative expressions from the three separate experiments were averaged for all 
samples and are represented as an average plus standard error. C. Data obtained from supernatant 
collected 4 days post beginning T cell polarization and addition of CpG and/or aIL10. The supernatant 
was analyzed via multiplex assay and the data indicates increased amount of IL-12 in samples that were 
given CpG and those that were given CpG and simultaneously neutralized of IL-10. D. Flow cytometry 
data showing that neutralizing the p40 subunit of IL-12 prevented IFN-γ production of Th17 polarized 




important cytokine that maintains Th17 polarization in the presence of CpG ODN and that 
it might be a potential future treatment to enhance adoptively transferred T cells.    
  
 
Figure 16. Simultaneously neutralizing IL-10 while priming Th17 cells with CpG decreases the 
long-term in vivo anti-tumor activity of adoptively transferred Th17 polarized TRP cells. A. 
C57/BL6 mice bearing s.c. B16F10 tumors established for 15 days were given 1.5e6 Th17 polarized TRP 
CD4+ T cells cultured with CpG and/ or aIL-10 monoclonal antibody. 1 day prior to infusion, mice 
received 5 Gy TBI and T cells were re-stimulated overnight with irradiated C57/BL6 splenocytes loaded 
with TRP peptide. B. Average tumor area of mice following T cell infusion indicates that Th17 cells 
polarized in the presence of both CpG and aIL10 antibody did not maintain long-term in vivo anti-tumor 





Chapter 5- General Discussion 
Lymphodepletion with chemotherapy and/or TBI enhances adoptive 
immunotherapy via several mechanisms. In addition to the removal of myeloid-derived 
suppressor cells, cytokine sinks and Treg cells, translocation of gut microflora by TBI 
enhances the outcome of therapy. This intriguing finding that bacterial infection can 
promote tumor regression are reminiscent of Coley's findings published long ago. 
In patients with advanced metastatic melamona, a non-myelablative regimen prior 
to infusion of tumor-infiltrating lymphocytes and bolus IL-2 resulted in an objective 
response rate of 50% in the absence of vaccination. Increasing this regimen to an intense 
myeloablative chemoradiation preparative regimen further augmented adoptive 
immunotherapy, resulting in an objective response rate of 72% and lead to more durable 
responses. While the tolerated doses of lymphodepletion are well established, these 
systemic approaches are not devoid of toxicities. In mice, we report here that escalating the 
intensity of lymphodepletion with TBI correlated with greater innate immune activation 
(Fig. 1A). Heightened innate activation was associated with greater impairment of the 
gastrointestinal tract, as evidenced by profound destruction of the colon and greater 
microbial LPS translocation (Fig. 1B-D). We wished to find an effective and safe way to 
activate the innate immune system without compromising the GI tract with intense 9 Gy 
TBI. Thus, we administered ultrapure LPS to non-irradiated mice receiving adoptive cell 
transfer (ACT). We found that LPS could not augment ACT-mediated tumor regression in 
non-irradiated mice (Fig. 2). However, we found that LPS could improve ACT treatment 
in mice given a non-myeloablative regimen of irradiation (Fig. 3). 
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We found that LPS improved ACT treatment by increasing CD25 expression, 
allowing for transferred cells to better compete for IL-2, and by enhancing initial 
proliferation post transfer, aiding in engraftment (Fig. 4). However, due to its inherent 
toxicity, we sought to use other clinically relevant TLR agonists to mimic the beneficial 
effects seen with LPS. We found that MPL or CpG ODN could also enhance outcomes in 
mice given nonmyeloablative ACT (Fig. 5). To further explore the potential of using TLR 
agonists to improve ACT, we hypothesized that we could obtain results similar to that of 
directly administering LPS to mice by instead priming CD8+ T cells with LPS in vitro 
during their rapid expansion. By washing LPS from the culture prior to infusion, we 
thought we could prevent the potential toxicity of this compound that might otherwise 
prevent the clinical translation of utilizing TLRs to enhance ACT. We found that in vitro 
priming of CD8+ T cells with LPS enhanced in vivo anti-tumor activity of the cells, 
increased expression of CD25 and increased their engraftment (Fig. 6). 
With this preliminary data we set out to explore some of the potential mechanisms 
for how TLR agonists augment the anti-tumor activity of CD8+ T cells. We found that LPS, 
MPL, PolyI:C or CpG could enhance their function, as indicated by their increased ability 
to secrete IFN-γ (Fig. 7A) and that the APC compartment was important for this enhanced 
function (Fig. 7C) . However, along with an increase in IFN-γ we found that LPS or CpG 
also induced an increase in the production of the immunoinhibitory cytokine, IL-10 (Fig. 
7). Yet, how IL-10 regulates CD8+ T cell responses to TLR signaling remains incompletely 
elucidated and is a major focus of this study.  
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Next, we wanted to determine if other TLR agonists besides LPS could enhance the 
activation of CD8+ T cells. We found that CpG significantly increased the expression of 
CD25 and ICOS on pmel-1 CD8+ T cells (Fig. 8). We found that neutralizing IL-10 while 
priming with CpG ODN further enhanced the expression of the activation markers CD25 
and ICOS (Fig. 9). Additionally, we wanted to determine how TLR agonists and IL-10 
impacted the memory phenotype of CD8+ T cells. Overall, priming pmel-1 T cells with 
TLR agonists increased the central memory phenotype of the cells (Fig, 10). Consistent 
with prior research that suggests IL-10 is responsible for creating optimal T cell memory, 
we found that neutralizing IL-10 caused cells to obtain a more effector memory-like 
phenotype (Fig. 10).101 Furthermore, when IL-10 was transiently neutralized while priming 
with CpG ODN, the cells were less central memory-like. These data suggest that IL-10 
may regulate the maturation of TLR agonist primed CD8+ T cells from fully activated 
effector cells into central memory T cells. We also found that priming CD8+ T cells with 
TLR agonists augmented their in vitro cytotoxicity and that transiently neutralizing IL-10 
also enhanced their function (Fig. 12).  
Subsequently, we wanted to test if our TLR-primed T cells in an in vivo model of 
melanoma to determine if our clinically relevant strategy was successful in regressing 
tumors. We found that priming CD8+ T cells with LPS, MPL or CpG ODN during primary 
expansion hindered tumor growth and enhanced survival when transferred into mice 
bearing melanoma (Fig. 13). We also found that neutralizing IL-10 during expansion of 
CD8+ T cells improved their survival and delayed tumor growth similar to priming cells 
with CpG (Fig, 14). Furthermore, we found that combining CpG ODN and blocking IL-10 
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did not enhance the anti-tumor response beyond control. Even though we were able to 
neutralize external sources of IL-10 with our monoclonal antibody, our methods did not 
account for the possibility of IL-10 autocrine regulation of CD8+ T cells.  In one 
experiment, we found that the production of IL-10 by pmel-1 CD8+ T cells increased when 
extracellular IL-10 was neutralized (not shown). Future experiments should account for 
the potential of IL-10 to be produced by CD8+ T cells and such techniques will be discussed 
in the future directions section of this thesis. 
Following our observation that CpG could be used to improve ACT therapy, we 
wanted to explore some of its immunomodulatory capabilities on different T cell subsets. 
We decided to explore Th17 cells due to their ability to mediate a superior melanoma 
regression in a mouse ACT model.100 A hallmark of Th17 cells is their plasticity, or the 
ability to convert from mainly IL-17A producers to IFN- producers. This Th17 plasticity 
has been associated with higher in vivo survival and self-renewal capacity compared to Th1 
cells.102 Using an IL-12 blocking antibody, we found that CpG induced Th17 cell plasticity 
and their conversion from IL-17 to IFN- was driven in part by IL-12 (Fig. 15A-D). We 
also found that IL-10 was important for preventing full Th1 polarization of CD4+ T cells 
in the presence of CpG and Th17 polarizing cytokines (Fig. 15A-D). In addition to the 
production of IL-12, CpG induced the production of other inflammatory cytokines 
including RANTES, CXCL-1, GM-CSF which could foster trafficking of other immune 
cells to sites of inflammation (not shown). We found that Th17 cells polarized in the 
presence of CpG while neutralized of IL-10 did not eradicate B16F10 melanoma as well 
as control Th17 cells (Fig, 17B & C). However, Th17 cells primed with CpG or neutralized 
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of IL-10 performed as well as control Th17 cells (Fig. 17B & C). Taken together, our data 
suggest that IL-10 is important for maintaining the prolonged production of IL-17 for Th17 
cells exposed to the TLR agonist CpG.  
  In conclusion, we found that clinically relevant TLR agonists such as CpG can be 
used to augment cell based anti-tumor therapies. Utilizing TLR agonists in a variety of 
ways, either through direct administration to patients or via ex vivo priming of extracted T 
cells may allow for possibility of avoiding myeloablative preparative regimens in ACT 
protocols. When employing TLR agonists to augment cell based therapies for melanoma, 
it is important to consider by-products of this microbial challenge. For this research, we 
focused on the role of IL-10 in response to TLR agonist stimulation of T cells. We found 
that IL-10 was important for maintaining central memory characteristics of CD8+ T cells 
and for preserving the anti-tumor activity of CpG primed Th17 cells. While these findings 
are interesting, further research needs to be conducted to understand the role of IL-10 in T 




Chapter 6- Future Directions and Conclusion 
In this study, we expand the potential of using TLR agonists for oncogenic 
malignancies by exploring their impact on tumor specific CD8+ T cells. We show that the 
clinically relevant TLR agonists MPL or CpG could potentially replace the need for 
myeloablative TBI in ACT regimens. While this study focused on administering various 
TLR agonists independently, it would be interesting to investigate the effects that 
combinations of different TLR agonists have. For instance it might prove efficacious to 
trigger both extracellular and intracellular TLRs simultaneously using both MPL and CpG, 
respectively. Or, using a combination of two intracellular derived TLR agonists such as 
PolyI:C and CpG could potentiate a robust anti-tumor response of adoptively transferred T 
cells. Furthermore, it would be interesting, although less clinically relevant and variable-
laden, if we exposed CD8+ T cells to various bacteria or viral lysates. This might better 
replicate in vivo microbial translocation caused by damage to the GI tract as opposed to 
using a purified TLR agonists. Perhaps microbial by-products other than the classic TLR 
agonists can induce stronger T cell responses. The possibilities and variability of 
combining the microbial landscape to augment the immune system are immense. However, 
the resulting immunoinhibitory consequences such as IL-10 production must be 
considered. 
Our data indicates that IL-10 plays an important role in maintaining a memory like 
phenotype of CD8+ T cells. It would be interesting to explore how addition of exogenous 
IL-10 during various stages of CD8+ T cell expansion impact the anti-tumor activity of the 
T cells. Additionally, it may be worthwhile to explore the effects of IL-10 production by 
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CD8+ T cells in response to combined TCR and TLR stimulation. Our method of 
neutralizing IL-10 was limited to extracellular sources so it would be intriguing to use TLR 
agonists in pmel-1 IL-10 knockout mice. In addition to focusing on IL-10, checkpoint 
blockade therapies might also increase the effectiveness of ACT regimens using TLR 
primed T cells. With the recent approval of αPD-1 receptor antibodies to treat advanced 
melanoma and non-small cell lung cancer, the future potential of immunotherapies for 
cancer treatment is robust.  
Furthermore, although we found that the CD62L expression was altered by TLR 
agonist priming and neutralization of IL-10, our methods were limited to short-term in vitro 
analysis. T cell memory generation was not tracked in a kinetic fashion which is a major 
limitation of this present study. In future studies, it would be interesting to track CD62L 
expression for an extended duration of time. Not only would we initially measure the 
expression of CD44 and CD62L shortly after T cell activation, we would extract transferred 
T cells from mice many weeks post ACT. It would be interesting to perform a 
biodistribution on the spleen and lymphnodes of the mice to determine if memory T cells 
were generated. Based on the present data in this study, we would expect for T cells primed 
with CpG to have a higher percentage of donor T cells in the lymphnodes that co-express 
CD44 and CD62L. We would also predict that T cells neutralized of IL-10 would have less 
memory T cells generated. This would be indicated by a decreased number of donor T cells 
present in the mouse weeks after ACT. 
In conclusion, it is important to reiterate that advanced metastatic melanoma is a 
devastating disease that requires a multilateral treatment approach. When the traditional 
46 
 
treatments such as surgery or chemotherapies have been exhausted, more sophisticated 
methods of immunotherapy are necessary. The goal is to induce curative responses in 
patients and adoptive cell therapy has proven efficacious for those left with limited options. 
By studying the mechanisms underlying TBI’s role in enhancing treatment outcomes in 
patients receiving ACT regimens, we arrive at a junction where the adoptive and innate 
immune systems meet. We utilized products from intestinal disruption and were able to 
show how some TLR agonists could augment T cell based anti-cancer immunity.  
Chapter 7-Materials and Additional Methods 
Mice and tumor lines. All mice were bred and housed at MUSC facilities. Female pmel-
1 TCR Tg mice were crossed with C57BL/6-Thy1.1 Tg mice to derive pmel-1 Thy1.1 
double Tg mice (C57BL/6-pmel-1-Thy1.1 mice; Jackson). Male TRP-1 mice used for Th17 
ACT experiments were purchased from Jackson. C57BL/6 (Taconic) were used as 
recipients in ACT experiments. Experiments were conducted with the approval of the 
MUSC Animal Use and Care Committee. B16-F10 (H-2b), a spontaneous, transplantable 
gp100+ murine melanoma, was maintained in culture media.  
In vitro activation of pmel-1 T cells. Pmel-1 mice are sacrificed via CO2 asphyxiation and 
cervical dislocation and spleens were extracted using sterile technique and placed in 2.00 
mM EDTA. Spleens were mechanically processed through 70μm filters using the plunger 
from a plastic syringe. Splenocytes were brought to a concentration 1-2e6/mL in T cell 
media and 1μg/mL hgp10025-33 peptide is added. Recombinant hIL-2 is added daily at 
100IU/mL (rhIL-2; Chiron Corp).  Assays were completed as indicated anywhere from 4-
8 days post activation with hgp10025-33 peptide. 
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Adoptive cell transfer, vaccination, cytokine administration and TLR agonists. Six-
ten week old mice were injected s.c. with 2-5 x 105 B16-F10 melanoma cells and treated 
10 d later with i.v. adoptive transfer of 1-3e6 pmel-1 CD8+ T cells in vitro activated-
splenocytes(to serve as a vaccination). 5 Gy TBI was given to mice on the day of ACT. In 
some experiments conducted with our NIH collaborator, mice were vaccinated with 2x107 
PFU of recombinant fowlpox virus expressing human gp100 (Therion Biologics). 3.6-36 
μg/dose of rhIL-2 was administered by i.p. injection twice daily for a total of five doses in 
some experiments. Ultra-pure LPS (Invivogen;0.1-50 μg s, i.v.), MPL (5 μg s, i.v. on day 
1), CpG ODN 1668 (10 μg s, i.v. daily for 4 consecutive days 
5'TCCATGACGTTCCTGATGCT-3'), Poly I:C (50 μg s, i.v), imiquimod (5% topical 
cream, everyday for three weeks), flagellin (200 μg s, i.v.), zymosan (250 μg s, i.v.) were 
administered 1 day post treatment with ACT. Tumors were measured with calipers and the 
perpendicular diameters were recorded. Experiments were performed in a blind, 
randomized fashion.  
Detection of serum LPS. For experiments in Figure 1, A LAL assay (QCL-1000; 
Cambrex) was used to analyze serum LPS on days 1-8.  
Enumeration of adoptively transferred cells and host CD11c+CD86+ DCs, and ex 
vivo cytokine release assay. At the indicated times, adoptively transferred pmel-1 thy1.1 
cells were enumerated. Transferred pmel-1 Thy 1.1 was calculated by multiplying the 
percent of Thy1.1/CD8+ T cells in the spleen by the absolute spleen count. Enumeration 
of host CD86highCD11c+ DCs was similarly performed. Six days after ACT, pmel-1 
thy1.1 cells were used for cytokine release assay via ELISA. Pmel-1 thy1.1 cells were 
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isolated from splenocytes and were co-cultured at a 1:2 ratio with irradiated splenocytes 
pulsed with titrated doses of hgp10025-33 peptide or unpulsed as negative controls.  
Functional and phenotypic assays. At the days indicated, Pmel-1 T cells cultured with 
TLR agonists and/or blocked of IL-10 will be assayed by flow cytometry, multi-analyte 
(Bio-Rad Pro™ Mouse Cytokine 23-Plex assay) and ELISA to determine their capacity to 
secrete IFN-γ, IL-2, TNF-α, IL-10, granzyme A and granzymeB on days 1-7. The 
activation and memory phenotype of the T cells will also be determined by their expression 
of CD62L, CD44, CD25, and ICOS. 
Mucosal barrier score. Colons were removed from mice and placed in 10% formalin for 
48 h, and then embedded in methylacrylate. 4-5-mm sections were taken along papillary-
optical axis. Sections were evaluated by a pathologist unaware of the identity of the groups 
using the scores as follows: normal architecture = 0, some signs of edema = 1, mild cell 
infiltration and reduction of crypts and goblets = 2, and severe cell infiltration and profound 
reduction of crypts and goblets = 3, severe cell infiltration and visually undetectable crypt 
and goblets = 4.  
P-mel Model. P-mel mice are a transgenic strain of mice that carry a rearranged T cell 
receptor transgene specific for human premalanosome protein gp100 (hgp100). They also 
carry the T lymphocyte specific Thy1.1 allele. Greater than 95% of the CD8+ T cells 
express the transgenic TCR based on expression of VB13. These transgenic CD8+ T cells 
account for approximately 20% of the total lymphocyte population.103,104 Tumor-specific 
CD8+ T cells can be expanded by adding hgp10025-33 peptide single-cell P-mel-1 
splenocytes plus IL-2.   
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TRP-1 Model. TRP-1 are a transgenic strain of mice that carry a rearranged T cell receptor 
transgene specific for the Tyrp-1 protein.100 CD4+ tumor specific T cells can be expanded 
from TRP-1 male splenocytes using C57/BL6 splenocytes plus TRP-1 peptide. The 
rearranged TCR contains Vβ14 chains which is used as a marker for the tumor-specific 
CD4+ T cells.  
Th17 cell culture/ polarization. Male TRP-1 mice were sacrificed via CO2 asphyxiation 
and cervical dislocation. Spleens were extracted under sterile conditions and TRP-1 
splenocytes were brought to single-cell suspension using manual dissociation and 70μm 
filter. TRP-1 splenocytes are then plated in an appropriate culture in CM while C57/BL6 
splenocytes are brought to a single cell suspension and loaded with TRP-1 peptide at a 
concentration of 1μg/mL.  C57/BL6 splenocytes + TRP-1 peptide mixture are vortexed 
intermittently for 30 minutes at 37C.  After at least 30 minutes the peptide loaded C57/BL6 
splenocytes are washed at least 2X and then combined with TRP-1 splenocytes. Th17 
polarizing media is then added to the cells so that the final concentrations are 2e6/mL TRP-
1 splenocytes, 4e5/mL TRP-1 peptide-loaded C57/BL6 splenocytes (5:1 ratio). Th17 media 
contains the following final concentrations of cytokines 30ng/mL hTGF-β, 100ng/mL hIL-
6, 10ng/mL hIL-1β, 100ng/mL hIL-21, 10μg/mL α-mouse IFN-γ, 10μg/mL α-mouse IL-4 
and 5μg/mL αmouse IL-2. 
Negative Selection. In some experiments, CD8+ T cells were purified using invitrogen™ 
Dynabeads® Untouched™ Mouse CD8 Cells kit. The purity of the selection was measured 
using flow cytometry and found to be greater than 87%. 
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Flow Cytometry Analysis and Cytokine Analysis. Flow cytometry data was analyzed 
using FlowJo V10 software. Graphs and statistical analysis were performed using Graph 
Prism 6. ANOVA statistical analysis was performed as indicated and represented as mean 
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